SRR1471435
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1311285 | GTEX | — | 0.973 |
| 2 | SRR1367870 | GTEX | — | 0.964 |
| 3 | SRR1324431 | GTEX | — | 0.964 |
| 4 | SRR1335651 | GTEX | — | 0.962 |
| 5 | SRR1329377 | GTEX | — | 0.961 |
| 6 | SRR1447693 | GTEX | — | 0.960 |
| 7 | SRR1418923 | GTEX | — | 0.957 |
| 8 | SRR1340907 | GTEX | — | 0.955 |
| 9 | SRR1478077 | GTEX | — | 0.954 |
| 10 | SRR1487107 | GTEX | — | 0.954 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.299 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.273 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.073 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.033 | Temsirolimus | — uncovered |